SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Conditions

• BRCA Gene Rearrangement
• Bladder Cancer
• Breast Cancer
• COVID
• Cancer
• Cancer Liver
• Cancer Prostate
• Cancer of Cervix
• Cancer of Colon
• Cancer of Esophagus
• Cancer of Kidney
• Cancer of Larynx
• Cancer of Liver
• Cancer of Neck
• Cancer of Pancreas
• Cancer of Rectum
• Cancer of Skin
• Cancer of Stomach
• Cancer, Advanced
• Cancer, Breast
• Cancer, Lung
• Cancer, Metastatic
• Carcinoma
• Central Nervous System Tumor
• Cholangiocarcinoma
• Endometrial Cancer
• Follicular Lymphoma
• Glioblastoma
• Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Melanoma
• Mismatch Repair Deficiency
• Myelodysplastic Syndromes
• Myelofibrosis
• Myeloproliferative Disorders
• Myeloproliferative Neoplasm
• Neuroendocrine Tumors
• Non Hodgkin Lymphoma
• Non Small Cell Lung Cancer
• Ovarian Cancer
• Testicular Cancer
• Urothelial Carcinoma

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Clinical Trial Matching — OTHER
  Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.

Study Details

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Key Dates

Start date

Jan 1, 2018

Status verified

Oct 2025

Primary completion

Dec 31, 2038

Completion

Jun 30, 2040

Study Design

Enrollment

50,000 participants (estimated)

Arms

• Arm: Study Group
  Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).

Primary Outcome Measure

Proportion of patients Eligible for CTE versus Actual CTE [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

• Fiona Evans, MS
  +1 (844) 627-7246
  [email protected]
• Diego Barrenechea, MD
  + 1 (646) 586-2753
  [email protected]

Locations (67)

Find similar trials in Birmingham, AL

Related Studies

• Evaluation for NCI Surgery Branch Clinical Research Protocols
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
  Recruiting · Northwestern University · Chicago, Illinois
• Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland